GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » Other Operating Expense

Qualis Innovations (Qualis Innovations) Other Operating Expense : $0.02 Mil (TTM As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Qualis Innovations Other Operating Expense?

Qualis Innovations's Other Operating Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.02 Mil.

Qualis Innovations's quarterly Other Operating Expense increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.02 Mil) but then declined from Dec. 2023 ($0.02 Mil) to Mar. 2024 ($0.00 Mil).

Qualis Innovations's annual Other Operating Expense stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then increased from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.02 Mil).


Qualis Innovations Other Operating Expense Historical Data

The historical data trend for Qualis Innovations's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualis Innovations Other Operating Expense Chart

Qualis Innovations Annual Data
Trend Jul06 Jul07 Jul08 Jul09 Jul10 Dec11 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only - -0.25 - - 0.02

Qualis Innovations Quarterly Data
Oct10 Jan11 Apr11 Sep11 Dec11 Mar12 Jun12 Sep12 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.02 -

Qualis Innovations Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qualis Innovations Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Qualis Innovations's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Qualis Innovations (Qualis Innovations) Business Description

Traded in Other Exchanges
N/A
Address
225 Wilmington West Chester Pike, Suite 200, No.145, Chadds Ford, PA, USA, 19317
Qualis Innovations Inc. is the holding company of mPathix Health, Inc. The company is focused on the development, production, and distribution of multi-modal pain management and Central Nervous System related solutions. It develops pain management products using a modality agnostic, virtual operating model. The company is developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen.
Executives
Bin Wang director 112 RICO DR. NORTH, MORGANVILLE NJ 07751